PrevEp is a US-based biotech founded by world leaders in epilepsy research to develop new therapies for epilepsy and seizure prevention. Its integrated preclinical and clinical teams accelerate translation from discovery to trials. PrevEp’s lead program, intranasal seletracetam (INSEL), is a rapid-acting, non-benzodiazepine “as-needed” treatment designed to prevent predictable seizures and treat acute repetitive seizures (ARS). INSEL is a new chemical entity and the only non-benzodiazepine antiseizure drug potent enough for nasal spray delivery. Oral seletracetam, a second-generation racetam related to levetiracetam, previously completed three Phase 2a trials (~170 patients) at UCB before being discontinued in favor of brivaracetam for strategic reasons. INSEL is being developed for reflex epilepsy (rare disease), triggered seizures (~50% of seizures), seizure-prediction paradigms, and ARS. First-in-human compassionate-use POC was completed in Europe (n=2).